Targeting IDH: The next big thing in AML

Blood

Volumn 122, Issue 16, 2013, Pages 2770-2771

  Levis, Mark ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXOGLUTARIC ACID; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; GENE EXPRESSION; GENE MUTATION; GENE SEQUENCE; HUMAN; MALIGNANT TRANSFORMATION; MOLECULARLY TARGETED THERAPY; PHENOTYPE; PRIORITY JOURNAL;

EID: 84888218028     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-09-522441     Document Type: Article

References (8)

1. Chaturvedi A, AraujoCruz MM, Jyotsana N, et al. Mutant IDH1 promotes leukemogenesis in vivo and can bespecifically targeted in human AML. Blood. 2013;122(16):2877-2887.
2. Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765-773.
3. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361(11):1058- 1066.
4. Abbas S, Lugthart S, Kavelaars FG, et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value. Blood. 2010;116(12):2122-2126.
5. Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739-744.
6. Xu W, Yang H, Liu Y, et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of a-ketoglutarate-dependent dioxygenases. Cancer Cell. 2011;19(1):17-30.
7. Pietrak B, Zhao H, Qi H, et al. A tale of two subunits: how the neomorphic R132H IDH1 mutation enhances production of aHG. Biochemistry. 2011;50(21):4804-4812.
8. Losman JA, Looper RE, Koivunen P, et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science. 2013;339(6127):1621-1625.